Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.

Journal of lipid research - 1 Jul 2013

Brautbar Ariel, Barbalic Maja, Chen Fengju, Belmont John, Virani Salim S, Scherer Steve, Hegele Robert A, Ballantyne Christie M

Abstract excerpt

Individuals with mixed dyslipidemia, including high triglycerides (TGs) and low high density lipoprotein cholesterol (HDL-C), have increased risk for coronary events. We examined the effect of rare genetic variants in the APOA5 gene region on plasma HDL-C, apolipoprotein A-I (apoA-I), and TG response to fenofibric acid monotherapy and in combination with statins. The APOA5 gene region was sequenced in 1,612...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acids
Share to Apolipoprotein A-I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoprotein A-V

Share to Apolipoproteins A

Share to Cholesterol, HDL

Share to Dyslipidemias

Share to Promoter Regions, Genetic

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 23633496
DOI: 10.1194/jlr.M034132
PMCID: PMC3679399

Genes

APOA5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.PMID 23633496Read ↗

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Semantic proximity Read ↗

Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.Semantic proximity Read ↗

Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.Semantic proximity Read ↗

Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.Semantic proximity Read ↗

What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants?Semantic proximity Read ↗

Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.Semantic proximity Read ↗

Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.Semantic proximity Read ↗

Genetics: Mutations in APOA5 or LDLR increase risk of myocardial infarction.Semantic proximity Read ↗

The "T" allele of apolipoprotein A5 rs2075291 is significantly associated with higher total cholesterol and triglyceride and lower high-density lipoprotein cholesterol levels in Asians: a meta-analysis.Semantic proximity Read ↗

Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people.Semantic proximity Read ↗

Genetics of HDL regulation in humans.Semantic proximity Read ↗

APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.